{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:27:03Z","timestamp":1786998423903,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.yebeh.2021.107898","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T01:25:51Z","timestamp":1616203551000},"page":"107898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Lack of observed impact of history or concomitant treatment of seasonal allergies or rhinitis on repeated doses of diazepam nasal spray administered per seizure episode in a day, safety, and tolerability: Interim results from a phase 3, open-label, 12-month repeat-dose safety study"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-6681","authenticated-orcid":false,"given":"Blanca","family":"Vazquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wheless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian L.","family":"Rabinowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Carrazana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.107898_b0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","article-title":"A review of intranasal formulations for the treatment of seizure emergencies","volume":"237","author":"Kapoor","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.yebeh.2021.107898_b0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1212\/CPJ.0000000000000099","article-title":"Development of benzodiazepines for out-of-hospital management of seizure emergencies","volume":"5","author":"Agarwal","year":"2015","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.yebeh.2021.107898_b0015","unstructured":"US Food and Drug Administration. Clinical superiority findings, https:\/\/www.fda.gov\/industry\/designating-orphan-product-drugs-and-biological-products\/clinical-superiority-findings; 2019 [accessed June 23, 2020]."},{"key":"10.1016\/j.yebeh.2021.107898_b0020","unstructured":"Sheikh J. What is the prevalence of allergic rhinitis (hay fever) in the US?, https:\/\/www.medscape.com\/answers\/134825-4370\/what-is-the-prevalence-of-allergic-rhinitis-hay-fever-in-the-us; 2018 [accessed May 15, 2020]."},{"key":"10.1016\/j.yebeh.2021.107898_b0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1164\/ajrccm.156.3.9607013","article-title":"Reduced airway absorption in seasonal allergic rhinitis","volume":"156","author":"Greiff","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.yebeh.2021.107898_b0030","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/j.1552-4604.1994.tb02051.x","article-title":"Nasal mucosal inflammation has no effect on the absorption of intranasal triamcinolone acetonide","volume":"34","author":"Argenti","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2021.107898_b0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1526-4610.2005.05005.x","article-title":"Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial","volume":"45","author":"Dowson","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.yebeh.2021.107898_b0040","doi-asserted-by":"crossref","first-page":"E349","DOI":"10.5489\/cuaj.4898","article-title":"Phase 1 pharmacokinetics and phase 3 efficacy of testosterone nasal gel in subjects with seasonal allergies","volume":"12","author":"Rogol","year":"2018","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.yebeh.2021.107898_b0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00544560","article-title":"Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin","volume":"33","author":"Larsen","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2021.107898_b0050","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF00315315","article-title":"The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis","volume":"45","author":"Shyu","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2021.107898_b0055","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00044011-200424110-00002","article-title":"Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis","volume":"24","author":"Davis","year":"2004","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.yebeh.2021.107898_b0060","article-title":"Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with seasonal allergic rhinitis with and without prior administration of oxymetazoline [abstract 718]","volume":"13","author":"Nave","year":"2009","journal-title":"Eur J Pain"},{"key":"10.1016\/j.yebeh.2021.107898_b0065","first-page":"83","article-title":"Vasomotor rhinitis and the systemic absorption of ipratropium bromide","volume":"28","author":"Kaila","year":"1990","journal-title":"Rhinology"},{"key":"10.1016\/j.yebeh.2021.107898_b0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF00202176","article-title":"Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant","volume":"48","author":"Lunell","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2021.107898_b0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2018.05.013","article-title":"Seizure cluster: Definition, prevalence, consequences, and management","volume":"68","author":"Jafarpour","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107898_b0080","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/0883073807306254","article-title":"Acceptance of the use of diazepam rectal gel in school and day care settings","volume":"22","author":"Terry","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2021.107898_b0085","unstructured":"Neurelis, Inc. Valtoco (diazepam nasal spray). Full Prescribing Information. San Diego, CA: Neurelis, Inc.; 2021."},{"key":"10.1016\/j.yebeh.2021.107898_b0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1081-1206(10)60854-X","article-title":"Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis","volume":"98","author":"Meltzer","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.yebeh.2021.107898_b0095","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2174\/1567201816666191029122740","article-title":"Drug delivery and targeting to the brain through nasal route: mechanisms, applications and challenges","volume":"16","author":"Kashyap","year":"2019","journal-title":"Curr Drug Deliv"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021001323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021001323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:37:29Z","timestamp":1761503849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021001323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":19,"alternative-id":["S1525505021001323"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107898","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of observed impact of history or concomitant treatment of seasonal allergies or rhinitis on repeated doses of diazepam nasal spray administered per seizure episode in a day, safety, and tolerability: Interim results from a phase 3, open-label, 12-month repeat-dose safety study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107898"}}